|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 324.56 USD | -0.23% |
|
+3.47% | +24.60% |
| Dec. 12 | FDA Approves Amgen's Uplizna (inebilizumab-cdon) for Generalized Myasthenia Gravis | CI |
| Dec. 12 | Morgan Stanley Adjusts Amgen Price Target to $304 From $329, Maintains Equalweight Rating | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bullish | Bullish |
| Resistance | 345.46 | 345.46 | 345.46 |
| Spread/Res. | -6.00% | -6.00% | -6.00% |
| Spread/Supp. | +7.06% | +7.06% | +8.68% |
| Support | 303.33 | 303.33 | 298.81 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- AMGN Stock
- Charts Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
